B细胞特异性激活蛋白在神经内分泌肿瘤中的表达Expression of PAX5 in Neuroendocrine Neoplasms
鲁永兰,杨文秀
LU Yonglan,YANG Wenxiu
摘要(Abstract)：
目的:观察B细胞特异性激活蛋白(PAX5)在神经内分泌肿瘤(NEN)中的表达。方法:经证实为NEN病例标本56例,用免疫组化SP法检测其石蜡包埋肿瘤组织中PAX5和Ki67表达,比较PAX5在不同肿瘤大小(肿块直径≤2 cm或>2 cm)、Ki67表达率(Ki67≤20%或>20%)及TNM分期(早期或晚期)中的表达情况。结果:PAX5在Ki67>20%病例中的阳性表达率(59.52%)高于Ki67≤20%病例(21.43%),在晚期病例(62.16%)高于早期病例(26.32%),差异有统计学意义(P<0.05);在不同肿块直径病例中的阳性率比较,差异无统计学意义(P=0.78)。结论:PAX5在NEN中有一定表达,表达与肿瘤增殖活性(Ki67表达率)及TNM分期有关。
Objective: To observe the expression of B cell-specific activator protein( PAX5) in neuroendocrine neoplasms( NENs). Methods: 56 confirmed NEN cases specimens were enrolled in this study. Immunohistochemical SP method was adopted to detect the expression of Pax5 and Ki67 in paraffin embedding tumor tissues. The positive expression rates of Pax5 was compared in different tumor size( mass diameter≤2 cm or > 2 cm),in different Ki67 expression rates( Ki67≤20% or > 20%) and in different TNM stage( early or late stage). Results: The positive expression rate of Pax5 in Ki67 >20% cases was 59. 52%,significantly higher than 21. 43% in Ki67 ≤ 20% cases( P < 0. 05). The positive expression rate of Pax5 in late stage was 62. 16%,significantly higher than 26. 32% in early stage( P <0. 05). There was no statistically significant difference in positive expression rate of Pax5 between different tumor size( P = 0. 78). Conclusion: There is a certain degree of expression of Pax5 in NENs,which is related to the proliferation activity of the tumor( Ki67 expression rate) and the TNM stage.
关键词(KeyWords)：
B细胞特异性激活蛋白;神经内分泌;肿瘤;免疫组织化学;染色法,SP
B cell-specific activator protein;neuroendocrine;neoplasm;immunohistochemistry;staining method,SP
基金项目(Foundation): 国家自然科学基金项目(81100299)
作者(Author):
鲁永兰,杨文秀
LU Yonglan,YANG Wenxiu
DOI: 10.19367/j.cnki.1000-2707.2016.05.018
参考文献(References)：
- [1]Scherubl H,Streller B,Stabenow R,et al.Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise:epidemiological changes in Germany[J].World J Gastroenterol,2013(47):9012-9019.
- [2]Starzynska T,Deptala A,Krolicki L,et al.Colorectal neuroendocrine neoplasms-management guidelines(recommended by the Polish Network of Neuroendocrine Tumours)[J].Endokrynol Pol,2013(6):494-504.
- [3]Fraenkel M,Kim M,Faggiano A,et al.Incidence of gastroenteropancreatic neuroendocrine tumours:a systematic review of the literature[J].Endocr Relat Cancer,2014(3):153-163.
- [4]Santoro A,Bica MG,Dagnino L,et al.Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia[J].Br J Haematol,2009(6):686-689.
- [5]Janczar K,Janczar S,Pastorczak A,et al.Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia[J].Leuk Res,2015(12):1455-1461.
- [6]Sica G,Vazquez MF,Altorki N,et al.PAX-5 expression in pulmonary neuroendocrine neoplasms:its usefulness in surgical and fine-needle aspiration biopsy specimens[J].Am J Clin Pathol,2008(4):556-562.
- [7]王乐民,张群,王晓虹.支气管类癌的外科治疗及预后分析[J].中国医学工程,2013(2):80.
- [8]Wang YH,Yang QC,Lin Y,et al.Chromogranin A as a marker for diagnosis,treatment,and survival in patients with gastroenteropancreatic neuroendocrine neoplasm[J].Medicine(Baltimore),2014(27):e247.
- [9]Nguyen R,Jett K,Harris GJ,et al.Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1[J].J Neurooncol,2014(2):307-313.
- [10]Panzuto F,Boninsegna L,Fazio N,et al.Metastatic and locally advanced pancreatic endocrine carcinomas:analysis of factors associated with disease progression[J].J Clin Oncol,2011(17):2372-2377.
- [11]Al Omar SY,Marshall E,Middleton D,et al.Increased numbers but functional defects of CD56+CD3+cells in lunger cancer[J].Int Immunol,2012(7):409-415.
文章评论(Comment)：
|
||||||||||||||||||
|
||||||||||||||||||